SCLC tumors in mice replicated from CTCs of patients -
By Lynda Williams, Senior medwireNews Reporter
The scientists used cells circulating tumor (CTC ) from patients with lung cancer small cell (SCLC) tumor to develop explants (CDXS) in mice which retain morphological and genetic characteristics of the original.
"CDXS as faithfully recapitulate the donor responses patients platinum and etoposide, standardization of care chemotherapy for SCLC, allowing clinically relevant studies of the biology and SCLC a model derived from the patient and easily generated sustainable for testing targeted therapies "report Caroline Dive, Cancer Research UK Manchester Institute and co-authors.
blood samples from six patients, SCLC naive vast stage chemotherapy were enriched for CTCs. three patients had then judged tumors sensitive to chemotherapy, while three patients had tumors refractory to the disease progression within 3 months of chemotherapy.
the researchers injected blood samples CTC- enriched in the flanks of immunodeficient mice and mice with CTCs four patients had palpable tumors within 4 months.
As indicated in Nature Medicine , diagnostic samples and CDXS has shown typical SCLC and SCLC micrometastases morphology were detected in the lungs and brain of a mouse on one of CDXS.
When three CDXS were treated with cisplatin and etoposide, had a significantly response to treatment than others, we had an intermediate response, and the last CDX did not respond.
CDX responses mirrored processing the response of tumors to chemotherapy, patients surviving for 9.7, 3.5 and 0.9 months, respectively.
and genetic analysis confirmed that the profiles of CDX matched the original tumor profiles, although there were differences in the CDX samples taken from the right and left sides of a mouse suggesting "the evolution of the tumor," say the researchers.
They cite the possibility to compare CDX profiles produced from the patient's blood samples taken before and after chemotherapy resistant relapse to drugs .
"[T] CDX models are unique, sequentially from available clinical samples, minimally invasive now provide an unprecedented opportunity to study the biology of SCLC diagnosis through treatment to progression" Dive et al write .
"CDX models will also facilitate the search for new druggable targets in SCLC and enable routine in e in vivo targeted therapies tests for a disease with clear unmet medical need."
medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon